世界の心臓を救った町 フラミンガム研究の55年

出版社： ライフサイエンス出版
著者：
発行日： 2004-06-30
分野： 医学一般  >  医学一般
ISBN： 9784897751924
電子書籍版： 2004-06-30 （初版第2刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,320 円(税込)

購入する

商品紹介

なぜFramingham Heart Study(フラミンガム研究)は世界中の臨床に影響を及ぼすものと成り得たのか?循環器疾患の予防医学・臨床疫学の礎，フラミンガム研究の知られざる全貌が今，明らかに。循環器疾患の予防医学・臨床疫学の礎，フラミンガム研究の知られざる全貌が今，明らかに。

目次

  • 表紙
  • 監修 / 取材協力 / 取材・編集協力 / 翻訳協力
  • 目次
  • 序
  • 第1章 フラミンガム研究のはじまり
  • 第2章 住民とのコラボレーション
  • 第3章 集積されていくエビデンス
  • 第4章 社会に波及する研究成果
  • 第5章 未来へ進化する疫学研究
  • あとがき
  • 巻末資料 The Framingham Heart Study 資金・情報フロー / 年表
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 フラミンガム研究のはじまり

P.39 掲載の参考文献
1. The Framingham Historical Society. Zeal for Healing : A Framingham Trait. Massachusetts, US : Framingham Historical Society ; 2001.
 
1) Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in Korea : preliminary report. JAMA 1953 ; 152 : 1090-3.
 
2) Lee PR. From the assistant secretary for health, US Public Health Service. JAMA 1994 ; 272 : 1315.
PubMed
2. Thomas Royle Dawber. The Framingham Study : The Epidemiology of Atherosclerotic Disease. Massachusetts, US and London, England : Harvard University Press ; 1980.
 
3. 中村好一. 基礎から学ぶ楽しい疫学. 医学書院 ; 2002.
 

第2章 住民とのコラボレーション

P.78 掲載の参考文献
1. Thomas Royle Dawber. The Framingham Study : The Epidemiology of Atherosclerotic Disease. Massachusetts, US and London, England : Harvard University Press ; 1980
 
2. Framingham Heart Studyホームページ (http://www.nhlbi.nih.gov/about/framingham/index.html)
 
3. 中村好一. 基礎から学ぶ楽しい疫学. 医学書院 ; 2002.
 
4. 宮原英夫, 丹後俊郎編. 医学統計学ハンドブック. 朝倉書店 ; 1995.
 
5. 三宅由子. 臨床データのまとめかた改訂第2版-研究計画から論文作成まで-. 杏林書院 ; 2001.
 

第3章 集積されていくエビデンス

P.126 掲載の参考文献
1. 築山久一郎, 大塚啓子. Framingham研究-50年にわたる大規模調査成績からの理にかなった教訓. Jpn Pharmacol Ther (薬理と治療) 2001 ; 29 : 493-510.
 
1) Stokes J, Dawber TR. The silent coronary : the frequency and clinical characteristics of unrecognized myocardial infarction in the Framingham study. Ann Intern Med 1959 ; 50 : 1359-69.
PubMed
2. 児玉和紀, 笠置文善, 増成直美. 内外の代表的なコホート研究の成果. 循環器科 1997 ; 41 : 532-44.
 
2) Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health 1957 ; 47 : 4-24.
 
3) Dawber TR, Kannel WB, Revotskie N, Stokes J, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease : six years' follow-up experience in the Framingham study. Am J Public Health 1959 ; 49 : 1349-56.
 
3. 吉成元孝. 高脂血症治療の進歩 フラミンガムスタディ. 日本臨牀 2001 ; 59 (増刊号 3) : 381-6.
 
4) Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med 1961 ; 55 : 33-50.
PubMed
4) In : Levy D, editor. 50 years of discavery : Medical milestones from the National Heart, Lung, and Blood institute's Framingham Heart Study. Center for Bio-Medical Communication ; 1999.
 
5) Thomas Royle Dawber. The Framingham Study : The Epidemiobgy of Atherosclerotic Disease. Massachusetts, US and London, England : Harvard University Press ; 1980
 
5) Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA 1970 ; 214 : 301-10.
PubMed
6) Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol 1971 ; 27 : 335-46.
PubMed
6) 中井継彦. 治療の歴史 : 糖尿病に合併する動脈硬化症の原因解明とその予防の治療. 治療学 1996 ; 30 : 109-14.
 
7) Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension. The Framingham study. Circulation 1980 ; 61 : 1179-82.
PubMed
7. 米国心臓協会ホームページ (http://www.americanheart.org/)
 
8) Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999 ; 138 : S205-10.
 
9) Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in the elderly : the Framingham Study. J Hypertens (Suppl) 1988 ; 6 : S3-9.
PubMed
10) Kannel WB, D'Agostino RB, Silbershatz H. Blood pressure and cardiovascular morbidity and mortality rates in the elderly. Am Heart J 1997 ; 134 : 758-63.
PubMed
11) Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993 ; 329 : 1912-7.
PubMed
12) Wilking SV, Belanger A, Kannel WB, D'Agostino RB, Steel K. Determinants of isolated systolic hypertension. JAMA 1988 ; 260 : 3451-5.
PubMed
13) Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997 ; 96 : 308-15.
PubMed
14) Wilson PWF, Kannel WB. Hypertension, other risk factors, and the risk of cardiovascular disease. ln : Laragh JH, Brenner BM, editors. Hypertension : pathophysiology, diagnosis, and management. Second edition. New York : Raven Press ; 1995 : 99-114
 
15) Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. ls pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999 ; 100 : 354-60.
 
16) Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001 ; 103 : 1245-9.
PubMed
17) Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000 ; 85 : 251-5.
PubMed
18) Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study : a cohort study. Lancet 2001 ; 358 : 1682-6.
PubMed
19) Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001 ; 345 : 1291-7.
PubMed
20) Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men : The Framingham Heart Study. JAMA 2002 ; 287 : 1003-10.
PubMed
21) Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannei WB. Risk factors for long-term coronary prognosis after initial myocardial infarction : the Framingham Study. Am J Epidemiol 1989 ; 130 : 469-80.
 
22) Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension : the Framingham Study. Am Heart J 1993 ; 125 : 1148-54.
PubMed
23) Vasan RS, Massaro JM, Wilson PW, Seshadri S, Wolf PA, Levy D, et al. Antecedent blood pressure and risk of cardiovascular disease : the Framingham Heart Study. Circulation 2002 ; 105 : 48-53.
PubMed
24) Kannel WB. Hypertension. Relationship with other risk factors. Drugs 1986 ; 31 (Suppl) 1 : t-11.
 
25) Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990 ; 322 : 1561-6.
PubMed
26) Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA, et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994 ; 272 : 33-6.
 
27) Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with ieft ventricular hypertrophy. Circulation 1994 ; 90 : 1786-93.
 
28) Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995 ; 25 : 879-84.
PubMed
29) McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure : the Framingham study. N Engl J Med 1971 ; 285 : 1441-6.
PubMed
30) Lloyd-Jones DM. The risk of congestive heart failure : sobering lessons from the Framingham Heart Study. Curr Cardiol Rep 2001 ; 3 : 1 84-90.
 
31) Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure : an epidemiologic perspective. J Am Coll Cardiol 1995 ; 26 : 1565-74.
PubMed
32) Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996 ; 156 : 1789-96.
PubMed
33) Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996 ; 275 : 1557-62.
PubMed
34) Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997 ; 336 : 1350-5.
PubMed
35) Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction : prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999 ; 33 : 1948-55.
 
36) Haider AW, Larson MG, Franklin SS, Levy D, Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003 ; 138 : 10-6.
PubMed
37) Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 1991 ; 266 : 231-6.
PubMed
38) Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002 ; 347 : 305-13.
PubMed
39) Gofman JW, Young W, Tandy R. lschemic heart disease, atherosclerosis, and longevity. Circulation 1966 ; 34 : 679-97.
 
40) Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971 ; 74 : 1-12.
PubMed
41) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 ; 62 : 707-14.
PubMed
42) Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983 ; 67 : 730-4.
PubMed
43) Castelli WP. The triglyceride issue : a view from Framingham. Am Heart J 1986 ; 112 : 432-7.
PubMed
44) Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor aiter myocardial infarction : the Framingham Study. Ann Intern Med 1991 ; 115 : 687-93.
 
45) Dawber TR. Summary of recent literature regarding cigarette smoking and coronary heart disease. Circulation 1960 ; 22 : 164-6.
PubMed
46) Doyle JT, Dawber TR, Kannel WB, Heslin AS, Kahn HA. Cigarette smoking and coronary heart disease. Combined experience of the Albany and Framingham studies. N Engl J Med 1962 ; 266 : 796-801.
PubMed
47) Castelli WP, Garrison RJ, Dawber TR, McNamara PM, Feinleib M, Kannel WB. The filter cigarette and coronary heart disease : the Framingham study. Lancet 1981 ; 2 : 109-13.
PubMed
48) Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as arisk factor for stroke. The Framingham Study. JAMA 1988 ; 259 : 1025-9.
 
49) Wilson PW, Hoeg JM, D'Agostino RB, Silbershatz H, Belanger AM, Poehlmann H, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med 1997 ; 337 : 516-22.
PubMed
50) Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population ; sixteen year follow-up study. Diabetes 1974 ; 23 : 105-11.
PubMed
51) Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure : the Framingham study. Am J Cardiol 1974 ; 34 : 29-34.
PubMed
52) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study. Ann Intern Med 1977 ; 87 : 393-7.
PubMed
53) Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979 ; 241 : 2035-8.
PubMed
54) Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988 ; 260 : 3456-60.
PubMed
55) Wilson PW, Cuppies LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991 ; 121 : 586-90.
 
56) Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC. Association of HbA1, with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992 ; 41 : 202-8.
PubMed
57) Meigs JB, D'Agostino RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997 ; 46 : 1594-600.
PubMed
58) Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease : the Framingham study. Ann Intern Med 1976 ; 85 : 447-52.
PubMed
59) Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995 ; 155 : 57-61.
PubMed
60) Kannel WB. Metabolic risk factors for coronary heart disease in women : perspective from the Framingham Study. Am Heart J 1987 ; 114 : 413-9.
PubMed
61) Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. lmpact of glucose intolerance and insulin resistance on cardiac structure and function : sexrelated differences in the Framingham Heart Study. Circulation 2003 ; 107 : 448-54.
PubMed
62) Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999 ; 353 : 89-92.
PubMed
63) Kannel WB. The Framingham Study : historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002 ; 5 : 27-37.
PubMed
64) Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease : a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983 ; 67 : 968-77.
PubMed
65) Garrison RJ, Feinleib M, Castelli WP, McNamara PM. Cigarette smoking as a confounder of the relationship between relative weight and long-term mortality. The Framingham Heart Study. JAMA 1983 ; 249 : 2199-203.
PubMed
66) Kannel WB. Habitual level of physical actMty and risk of coronary heart disease : the Framingham study. Can Med Assoc J 1967 ; 96 : 811-2.
 
67) Kannel WB, Sorlie P. Some health benefits of physical activity. The Framingham Study. Arch Intern Med 1979 ; 139 : 857-61.
PubMed
68) Gordon T, Kagan A, Garcia-Palmieri M, Kannel WB, Zukel WJ, Tillotson J, et al. Diet and its relation to coronary heart disease and death in three populations. Circulation 1981 ; 63 : 500-15.
PubMed
69) Posner BM, Cobb JL, Belanger AJ, Cupples LA, D'Agostino RB, Stokes J. Dietary lipid predictors of coronary heart disease in men. The Framingham Study. Arch Intern Med 1991 ; 151 : 1181-7.
PubMed
70) Gordon T, Kannel WB. Drinking and its relation to smoking, BP, blood lipids, and uric acid. The Framingham study. Arch Intern Med 1983 ; 143 : 1366-74.
PubMed
71) Gordon T, Kannel WB. Drinking and mortality. The Framingham Study. Am J Epidemiol 1984 ; 120 : 97-107.
PubMed
72) Felson DT, Zhang Y, Hannan MT, Kannel WB, Kiel DP. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995 ; 142 : 485-92.
PubMed
73) Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979 ; 90 : 85-91.
PubMed
74) Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991 ; 121 : 293-8.
PubMed
75) Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease : the Framingham Study. Am Heart J 1990 ; 120 : 963-9.
PubMed
76) Kannel WB. Risk stratification in hypertension : new insights from the Framingham Study. Am J Hypertens 2000 ; 13 (1 Pt 2) : 3S-10S.
 
77) Kannel WB, Wilson PW. Efficacy of Iipid profiles in prediction of coronary disease. Am Heart J 1992 ; 124 : 768-74.
 
78) Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998 ; 97 : 1837-47.
PubMed

第4章 社会に波及する研究成果

P.175 掲載の参考文献
1. 戸嶋裕徳, 橋本隆一, 鶴田 真. 虚血性心疾患の疫学 欧米における虚血性心疾患の予防の実績. CURRENT THERAPY 1993 ; 11 : 37-43.
 
1) Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. JAMA 1967 ; 202 : 1 028-34.
 
2. 米国医学図書館 (National Library of Medicine : NML) ホームページ (http://profiles.nlm.nih.gov/NN/Views/Exhibit/narrative/smoking.html)
 
2) Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979 ; 242 : 2562-71 Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. ll. Mortality by race-sex and age. JAMA 1979 ; 242 : 2572-7.
 
3) Management Committee. The Australian therapeutic triai in mild hypertension. Lancet 1980 ; 1 : 1261-7.
 
4) Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986 ; 293 : 1145-51.
PubMed
5) Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet 1985 ; i : 1349-54.
 
6) SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension : final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991 ; 265 : 3255-64.
 
7) Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, Eliasson K, et al. Metoprolol versus thiazide diuretics in hypertension ; morbidity results from the MAPHY study. Hypertension 1991 ; 17 : 579-88.
PubMed
8) Kostis JB, Davis BR, Cutler J, Grimm RH, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997 ; 278 : 212-6.
PubMed
9) Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 ; 342 : 145-53. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000 ; 342 : 154-60.
 
10) Hansson L, Zanchetti A, Carruthers SG, Dahbf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension ; principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998 ; 351 : 1755-62.
 
11) Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al for the systolic hypertension in Europe (Syst-Eur) trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997 ; 350 : 757-64.
PubMed
12) Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients : cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet 1999 ; 354 : 1751-6.
PubMed
13) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002 ; 288 : 2981-97.
PubMed
14) Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality : the Framingham heart study 1950 to 1990. Circulation 1996 ; 93 : 697-703.
PubMed
15) Mosterd A, D'Agostino, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989, N Engl J Med 1999 ; 340 : 1221-7.
PubMed
16) Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 ; 344 : 1651-8.
 
17) Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 2001 ; 357 : 1385-90.
PubMed
18) Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved trial. Lancet 2003 ; 362 : 777-81.
PubMed
19) Lipid research clinics program. The lipid research clinics coronary primary prevention trial results : I. reduction in incidence of coronary heart disease. JAMA 1984 ; 251 : 351-64.
 
20) Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study : primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia : safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987 ; 317 : 1237-45.
PubMed
21) Scandinavian simvastatin survival study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease : the Scandinavian simvastatin survival study (4S). Lancet 1994 ; 344 : 1383-9.
 
22) Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K. Wilhelmsen, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastation survival study (4S). Circulation 1998 ; 97 : 1453-60.
 
23) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 ; 335 : 1001-9.
PubMed
24) Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the loint national committee on prevention, detection, evaluation, and treatment of high blood pressure : the JNC 7 report JAMA 2003 ; 289 : 2560-72.
 
25) European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 ; 21 : 1011-53.
 
26) World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO) /International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 ; 21 : 1 983-92.
 
27) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 ; 157 : 2413-46.
PubMed
28) Lloyd-Jones DM, Evans JC, Larson MG, O, Donnell CJ, Wilson PW, Levy D. Crossclassification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med 1999 ; 159 : 2206-12.
PubMed
29) Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Herat Study. Lancet 2001 ; 358 : 1682-6.
 
30) Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population og Japanese elderly : the Hisayama study. Arch Intern Med 2003 ; 163 : 361-6.
 
31) PROGRESS collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 ; 358 : 1033-41.
PubMed
32) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993 ; 269 : 3015-23.
 
33) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 ; 285 : 2486-97.
 
34) Akosah KO, Schaper A, Cogbill C. Preventing myocardial infarction in the young adult in the first place : how do the National Cholesterol Education Panel III guide-lines perform? J Am Coll Cardiol 2003 ; 41 : 1475-9.
 
35) Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome : report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004 ; 109 : 433-8.
PubMed
36) Loria CM, Obarzanek E, Ernst ND. Choose and prepare foods with less salt : dietary advice for all Americans. J. Nutr. 2001 ; 131 : 536S-51S.
PubMed

第5章 未来へ進化する疫学研究

P.214 掲載の参考文献
1) Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999 ; 159 : 1077-80.
PubMed
1. 上島弘嗣. 1980年循環器疾患基礎調査の追跡研究 (NIPPON DATA). 日循協誌 1997 ; 31 (3)
 
2) Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003 ; 289 : 1251-7.
PubMed
3) Kannel WB, Wolf PA, Castelli WP, D'Agostino RB, et al. Fibrinogen and risk of cardiovascular disease ; the Framingham Study. JAMA 1987 ; 258 : 1183-6.
PubMed
4) Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring study. Circulation 2002 ; 106 : 2919-24.
PubMed
5) O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, et al. Evidence for association and genetic linkage of the angiotensin-conberting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998 ; 97 : 1766-72.
 
6) Feng D, Lindpaintner K, Larson MG, O'Donnell CJ, Lipinska I, Sutherland PA, et al. Platelet glycoprotein 3a PIA polymorphism, fibrinogen, and platelet aggregability : the Framingham Heart Study. Circulation 2001 ; 104 : 140-4.
 
7) Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003 ; 290 : 2263-70.
PubMed
8) Hannan MT, Felson DT, Anderson JJ. Bone mineral density in elderly men and women : results from the Framingham osteoporosis study. J Bone Miner Res 1992 ; 7 : 547-53.
PubMed
9) Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, et al. Risk factors for longitudinal bone loss in elderly men and women : the Framingham Osteoporosis Study. J Bone Miner Res 2000 ; 15 : 710-20.
PubMed
10) Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice : cross sectional population based study. BMJ 2002 ; 325 : 1271.
PubMed
11) Wilson PW, Christiansen JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk factor screening : the Framingham Offspring Study. JAMA. 1989 ; 262 : 41-4.
PubMed
12) Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Wlliams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes 2003 ; 52 : 2160-7.
 
13) Port S, Demer L, Jennrich R, Walter D, Garfinkel A. Systolic blood pressure and mortality. Lancet 2000 ; 35 : 175-80.
 

あとがき

P.221 掲載の参考文献
1. The Framingham Heart Studyホームページ (http://www.nhlbi.nih.gov/about/framingham/index.html)
 
1) Dawber TR, Stokes J 3rd. Rheumatic heart disease in the Framingham study. N Engl J Med 1956 ; 255 : 1228-3.
PubMed
2) Stokes J 3rd, Dawber TR. The "silent coronary" : the frequency and clinical characteristics of unrecognized myocardial infarction in the Framingham study. Ann Intern Med 1959 ; 50 : 364-9.
 
2. 治療の歴史（http://www.lifescience.jp/ebm/medhist/)
 
3. 降圧薬承認, 使用状況の歴史. In : 蔵本築監修. 臨床高血圧の100年-過去からみえてくる未来-. ライフサイエンス出版 ; 1997. p. 14-7.
 
3) Dawber TR, Kannel WB, Revotskie N, Stokes J 3rd, Kagan A, Gordon T : Some factors associated with the development of coronary heart disease : six years' follow-up experience in the Framingham study. Am J Public Health 1959 ; 49 : 1349-56.
 
4) Dawber TR: Summary of recent literature regarding cigarette smoking and coronary heart disease. Circulation 1960 ; 22 : 164-6.
PubMed
5) Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd I. Factors of risk in the development of coronary heart disease-six year follow-up experience; the Framingham study. Ann Intern Med 1961 ; 55 : 33-50.
PubMed
6) Kannel WB, Dawber TR, McNamara PM. Vascular disease of the brain-epidemiologic aspects: the Framingham Study. Am J Public Health 1965 ; 55 : 1355-66.
 
7) Kannel WB. Habitual level of physical activity and risk of coronary heart disease ; the Framingham Study. Can Med Assoc J 1967 ; 96 : B11-2.
 
8) Thomas HEJ, Kannel WB, McNamara PM. Obesity: a hazard to health. Med Times 1967 ; 95 : 1099-106.
 
9) Truett J, Cornfield J, Kannel WB. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis 1967 ; 20 : 511-24.
 
10) Kannel WB, Wolf PA, Verter J, McNamara PM : Epidemiologic assessment of the role of blood pressure in stroke ; the Framingham Study. JAMA 1970 ; 214 : 301-10.
PubMed
11) McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure : the Framingham Study. N Engl J Med 1971 ; 285 : 1441-46.
PubMed
12) Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease ; the Framingham Study. Am J Cardiol 1971 ; 27 : 335-45.
PubMed
13) Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974 ; 23 : 105-11.
PubMed
14) Kannel WB, Hjortland MC, McNamara PM, Gordon T: Menopause and risk of cardiovascular disease; the Framingham study. Ann Intern Med 1976 ; 85 : 447-52.
PubMed
15) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 ; 62 : 707-14.
PubMed
16) Haynes SG, Feinleib M, Levine S, Scotch N, Kannel WB: The relationship of psychosocial factors to coronary heart disease in the Framingham study ; II. Prevalence of coronary heart disease. Am J Epidemiol 1978 ; 107 : 384-402.
PubMed
17) Wolf PA, Dawber TR, Thomas HEJ, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology 1978 ; 28 : 973-77.
 
18) Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension. The Framingham Study. Circulation 1980 ; 61 : 1179-82.
PubMed
19) Kannel WB. Update on the role of cigarette smoking in coronary artery disease. Am Heart J 1981 ; 101 : 319-28.
PubMed
20) Gordon T, Kagan A, Garcia-Palmieri M, Kannel WB, Zukel WJ, Tillotson J et al. Diet and its relation to coronary heart disease and death in three populations. Circulation 1981 ; 63 : 500-15.
PubMed
21) Savage DD, Garrison RJ, Devereux RB, Castelli WP, Anderson SJ, Levy D et al. Mitral valve prolapse in the general population. 1. Epidemiologic features: the Framingham Study. Am Heart J 1983 ; 106 : 571-76.
PubMed
22) Anderson KM, Castelli WP, Levy D. Cholesterol and mortality : 30 years of follow-up from the Framingham study. JAMA 1987 ; 257 : 2176-80.
PubMed
23) Kannel WB, Wolf PA, Castelli WP, D'Agostino RB ; Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 1987 ; 258 : 1183-6.
PubMed
24) Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987 ; 317 : 1169-74.
 
25) Wilson PWF, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988 ; 8 : 737-41.
 
26) Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988 ; 259 : 1025-29.
PubMed
27) Wilking SV, Belanger AJ, Kannel WB, D'Agostino RB, Steel K. Determinants of isolated systolic hypertension. JAMA 1988 ; 260 : 3451-55.
 
28) Eaker ED, Castelli WP. Type A behavior and mortality from coronary disease in the Framingham Study. N Engl J Med 1988 ; 319 : 1480-81.
PubMed
29) Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocysteine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990 ; 16 : 1114-19.
 
30) Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993 ; 329 : 1912-17.
PubMed
31) Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA et al: Left ventricular mass and risk of stroke in an elderly cohort. JAMA 1994 ; 272 : 33-6.
 
32) Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population- based cohort. The Framingham Heart Study. JAMA 1994 ; 271 : 840-44.
 
33) Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994 ; 272 : 1666-71.
 
34) Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation 1994 ; 90 : 1688-95.
 
35) Vasan RS, Levy D: The role of hypertension in the pathogenesis of heart failure ; a clinical mechanistic overview. Arch Intern Med 1996 ; 156 : 1789-96.
PubMed
36) Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997 ; 336 : 1350-5.
PubMed
37) O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998 ; 97 : 1766-72.
 
38) Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998 ; 97 : 1837-47.
PubMed
39) Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999 ; 100 : 354-60.
PubMed
40) Port S, Demer L, Jennrich R, Walter D, Garfinkel A. Systolic blood pressure and mortality. Lancet 2000 ; 355 : 175-80.
PubMed
41) Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB et al. Does the relation of blood pressure to coronary heart disease risk change with aging? ; the Framingham heart study. Circulation 2001 ; 103 : 1245-9.
PubMed
42) Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001 ; 345 : 1291-7.
PubMed
43) Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study : a cohort study. Lancet 2001 ; 358 : 1682-6.
PubMed
44) Vasan RS , Massaro JM, Wilson PW, Seshadri S, Wolf PA, Levy D et al. Antecedent blood pressure and risk of cardiovascular disease : the Framingham heart study. Circulation 2002 ; 105 : 48-53.
PubMed
45) Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. N Engl J Med 2002 ; 347 : 305-13.
PubMed
46) Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women ; the Framingham heart study. Circulation 2002 ; 106 : 1189-91.
PubMed
47) Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB et al. Lifetime risk for developing congestive heart failure ; the Framingham heart study. Circulation 2002 ; 106 : 3068-72.
PubMed
48) Fox CS, Vasan RS, Parise H, Levy D, O'Donnell CJ, D'Agostino RB et al. Mitral annular calcification predicts cardiovascular morbidity and mortality ; the Framingham heart study. Circulation 2003 ; 107 : 1492-6.
PubMed
49) Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio heart and Framingham offspring studies. Diabetes 2003 ; 52 : 2160-7.
 

書評

最近チェックした商品履歴

Loading...